Krystal Biotech
KRYS
422 hedge funds and large institutions have $11.1B invested in Krystal Biotech in 2026 Q2 according to their latest regulatory filings, with 94 funds opening new positions, 177 increasing their positions, 108 reducing their positions, and 36 closing their positions.
161% more first-time investments, than exits
New positions opened: 94 | Existing positions closed: 36
64% more repeat investments, than reductions
Existing positions increased: 177 | Existing positions reduced: 108
51% more capital invested
Capital invested by funds: $7.32B → $11.1B (+$3.75B)
21% more call options, than puts
Call options by funds: $95.1M | Put options by funds: $78.9M
20% more funds holding in top 10
Funds holding in top 10: 10 → 12 (+2)
15% more funds holding
Funds holding: 368 → 422 (+54)
5.68% more ownership
Funds ownership: 97.07% → 102.75% (+5.7%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VC
Vestor Capital
Chicago,
Illinois
|
+$209M |
| 2 |
BlackRock
New York
|
+$72M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$60.5M |
| 4 |
William Blair Investment Management
Chicago,
Illinois
|
+$48.7M |
| 5 |
Vanguard Portfolio Management
Malvern,
Pennsylvania
|
+$35.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
-$121M |
| 2 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
-$63.9M |
| 3 |
Marshall Wace
London,
United Kingdom
|
-$17.7M |
| 4 |
B
Braidwell
Stamford,
Connecticut
|
-$16M |
| 5 |
Capital World Investors
Los Angeles,
California
|
-$14M |
KRYS Hedge Fund Activity: Q2 2026 in Review
422 of the 8,297 institutional investors tracked by Wall St. Rank reported a position in Krystal Biotech (KRYS) for Q2 2026, worth a combined $11.1B — up 51% from $7.32B a quarter earlier.
Buyers outnumbered sellers: 94 funds opened new KRYS positions and 36 closed out — a net gain of 58 holders — while 177 added to existing stakes and 108 trimmed.
The largest buyer was Vestor Capital, adding an estimated $209M. The largest seller was Bellevue Group, cutting an estimated $121M.
- 422 institutional investors held Krystal Biotech (KRYS) as of Q2 2026, up from 368 in Q1 2026.
- Funds reported $11.1B of Krystal Biotech stock for Q2 2026, up 51% quarter-over-quarter.
- 94 funds opened new Krystal Biotech positions in Q2 2026 and 36 closed out, a net change of +58 holders.
- The largest Krystal Biotech buyer in Q2 2026 was Vestor Capital, an estimated $209M added.
- The largest Krystal Biotech seller in Q2 2026 was Bellevue Group, an estimated $121M sold.
Based on aggregated 13F filings for Q2 2026.